Recent Price Movement and Market Context
On 24 Nov 2025, Biofil Chemicals & Pharmaceuticals recorded a closing price of Rs.37.71, the lowest level in the past year. This price point comes after three consecutive sessions of decline, during which the stock has returned -4.39%. The daily change on the latest trading day was -1.69%, underperforming the Pharmaceuticals & Biotechnology sector by 1.66%. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent downward trend.
In contrast, the broader market has shown resilience. The Sensex opened 88.12 points higher and was trading at 85,455.79, a 0.26% gain, approaching its 52-week high of 85,801.70. The Sensex has experienced a three-week consecutive rise, gaining 2.69% over this period, supported by strong performances from mega-cap stocks. The index is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a generally bullish market environment.
Long-Term Performance and Financial Metrics
Over the past year, Biofil Chemicals & Pharmaceuticals has delivered a total return of -36.62%, significantly lagging behind the Sensex’s 8.01% gain. The stock’s 52-week high was Rs.72, highlighting the extent of the decline to the current low. This underperformance extends beyond the last year, with the company consistently trailing the BSE500 index in each of the past three annual periods.
Financially, the company’s long-term growth in operating profits has shown a compound annual growth rate (CAGR) of -24.21% over the last five years. This negative growth rate reflects a contraction in core profitability. The company’s ability to service its debt is limited, with an average EBIT to interest ratio of 0.66, indicating that earnings before interest and tax cover interest expenses by less than one and a half times on average. Return on equity (ROE) has averaged 5.27%, suggesting modest profitability relative to shareholders’ funds.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Recent Operational Highlights
Despite the stock’s price challenges, Biofil Chemicals & Pharmaceuticals has reported some positive developments in its recent financial results. For the latest six-month period, net sales stood at Rs.19.97 crores, reflecting growth of 84.06%. Profit after tax (PAT) for the same period was Rs.2.49 crores, indicating an increase compared to prior periods. The company’s return on equity for this timeframe was 13.4%, which is notably higher than its longer-term average.
Valuation metrics suggest the stock is trading at a price-to-book value of 2.9, which is lower than the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector. The price-earnings-to-growth (PEG) ratio is approximately 0.1, reflecting the relationship between the company’s price, earnings growth, and valuation.
Shareholding and Market Position
The majority of Biofil Chemicals & Pharmaceuticals’ shares are held by non-institutional investors. This ownership structure may influence trading patterns and liquidity. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performances across different market segments.
Biofil Chemicals & Pharmaceuticals or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Financial Indicators
To summarise, Biofil Chemicals & Pharmaceuticals has experienced a notable decline in its stock price, reaching Rs.37.71, its lowest level in the past year. The company’s financial indicators reveal a contraction in operating profits over the medium term, limited debt servicing capacity, and modest returns on equity. While recent sales and profit figures show improvement, these have not yet translated into a recovery in the stock price or broader market confidence.
The stock’s valuation metrics indicate it is trading at a discount relative to sector peers, but this is set against a backdrop of consistent underperformance relative to benchmark indices. The broader market environment remains positive, with the Sensex near its 52-week high and supported by strong mega-cap performances, contrasting with the challenges faced by Biofil Chemicals & Pharmaceuticals.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
